Jean-Pierre Sommadossi - Jan 31, 2023 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
President, CEO, and Chairman, Director
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for Jean-Pierre Sommadossi
Stock symbol
AVIR
Transactions as of
Jan 31, 2023
Transactions value $
$0
Form type
4
Date filed
2/2/2023, 05:33 PM
Previous filing
Feb 2, 2022
Next filing
Mar 3, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Award $0 +520K $0.00 520K Jan 31, 2023 Common Stock 520K Direct F1, F2
transaction AVIR Stock Option (Right to Buy) Award $0 +729K $0.00 729K Jan 31, 2023 Common Stock 729K $4.63 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The RSUs vest in three (3) equal annual installments on the first three anniversaries of the grant date such that the RSUs are fully vested on January 31, 2026.
F3 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2023 such that the option is fully vested on January 31, 2027.